Sanofi stock gains as Barclays raises price target and Nuvaxovid rollout expands

Published on 09/12/2026 at 14:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi stock traded around EUR 73 on Euronext Paris on September 12, 2026 after Barclays lifted its price target to EUR 83 the same day. The move follows Sanofi’s expanded role in the global Nuvaxovid vaccine rollout for 2026-2027.

Schwarzweiß-Reportagefoto einer Newsroom-Redaktion mit Blick auf Paris — Vivendi SE (FR0000127771) zählt zu Frankreichs Medienkonzernen; die Schwarzweiß-Reportage zeigt eine Pariser Redaktion, Illustration mit AI erstellt.

Sanofi stock (ISIN FR0000127771) was quoted near EUR 73.26 on Euronext Paris on September 12, 2026, leaving the pharma group valued at over EUR 80 billion and reflecting a modest gain versus recent sessions. According to Boursorama on September 12, 2026, Barclays maintained its Market-Weight stance but raised its Sanofi price target from EUR 79 to EUR 83, signaling increased confidence in the earnings trajectory.

Barclays lifts target as Sanofi deepens vaccine role

The latest analyst action provides a clear anchor for Sanofi stock on September 12, 2026. According to Boursorama on September 12, 2026, Barclays now sees fair value at EUR 83 per share, up from EUR 79 previously, while keeping its recommendation at Market-Weight. The 5.1 percent uplift in the price target reflects a more constructive view on Sanofi’s profit outlook, with consensus estimates on that page pointing to a net income per share of EUR 7.83 for 2025, EUR 8.56 for 2026 and EUR 9.08 for 2027, alongside an implied forward price-earnings ratio moving from 9.64 times to 8.32 times over that horizon.

Strategically, Sanofi is also strengthening its role in the global vaccine market. As Simply Wall St reported on September 11, 2026, Sanofi is being entrusted with global commercial activities for Nuvaxovid, Novavax’s COVID-19 vaccine, over the 2026-2027 period. The analysis points towards an illustrative EUR 94.28 fair value for Sanofi shares based on that broader vaccine role and earnings power, which stands noticeably above the mid-70 euro trading region and underlines the upside potential some models see if execution and margins hold.

Key figures, dividends and voting-rights structure

For investors, the earnings and dividend trajectory is central. According to the forecast table shown by Boursorama as of September 12, 2026, the expected dividend per Sanofi share stands at EUR 4.12 for 2025, EUR 4.26 for 2026 and EUR 4.44 for 2027. At the 2026 forecast level, this points to a prospective dividend yield of about 5.65 percent, up from 5.46 percent on the 2025 expectation and rising further to 5.88 percent on the 2027 estimate, assuming the share price stays in a comparable range. With forecast net income per share increasing from EUR 7.83 in 2025 to EUR 8.56 in 2026 and EUR 9.08 in 2027, the market is effectively pricing a gradual mid-single-digit to high-single-digit earnings growth profile across those years.

Sanofi’s capital structure also remains broad, with a large free float. According to Futunn News citing a company disclosure on September 12, 2026, Sanofi reported that as of August 31, 2026 it had 1,207,773,393 issued shares outstanding. The same notice shows 1,336,151,933 real voting rights, excluding treasury shares, and 1,343,318,995 theoretical voting rights including treasury shares, pursuant to French market regulations. This structure means that each incremental earnings improvement translates directly into a high absolute profit figure, which is important when comparing Sanofi to global peers.

In terms of valuation comparisons, one recent cross-sector comment helps frame Sanofi’s multiple. As Yahoo Finance UK reported on September 11, 2026 in coverage of Novo Nordisk and its peers, Sanofi was trading at about 8 times earnings, compared with roughly 10 times for GSK. That snapshot underscores that despite its sizeable scale and vaccine role, Sanofi still trades at a discount to some European competitors on a price-earnings basis, a factor that may be contributing to the constructive stance taken by houses like Barclays.

Stock level, range and investor perspective

Sanofi’s primary listing is on Euronext Paris under the ticker SAN, and the current reference price comes from that venue. Around 17:39 on September 12, 2026, Boursorama recorded trades at EUR 73.26, with several prints at that level in the final minutes of the session. On that basis, the Barclays target of EUR 83 implies a potential upside of roughly EUR 9.74 per share, or around 13 percent, if the stock were to move fully in line with that revised objective. When set against the EUR 94.28 fair-value indication referenced by the Simply Wall St model, the gap becomes even more pronounced, highlighting that Sanofi’s valuation still leaves room for differing views among analysts and quantitative frameworks.

For investors, the combination of a rising dividend stream, low-double-digit implied upside to key price targets and a relatively modest earnings multiple compared to peers forms the core of the current Sanofi equity story. The detailed voting-rights disclosure from August 31, 2026 confirms a transparent governance structure with over 1.3 billion theoretical voting rights outstanding, while the Nuvaxovid rollout for 2026-2027 adds an operational growth vector beyond the traditional pharmaceuticals and vaccines portfolio. The main risk factor flagged in recent commentary is that execution on these vaccine agreements and broader R&D programs must stay on track to justify the rising earnings and dividend forecasts; any setback in clinical data or pricing pressure could narrow the valuation discount that currently appears supportive.

Sanofi stock price and market data

At the close referenced by Boursorama on September 12, 2026, Sanofi stock on Euronext Paris traded at EUR 73.26, providing the benchmark price in its home market. Using the reported issued share count of 1,207,773,393 as of August 31, 2026 from the Futunn summary of Sanofi’s voting-rights notice, this price level corresponds to an equity market capitalization in the region of EUR 88.5 billion as of early September 2026. In turn, that capitalization underpins Sanofi’s role as a leading European healthcare constituent, and the stock’s valuation metrics, including the roughly 8 times earnings multiple indicated in the Novo Nordisk peer comparison, will continue to be closely watched by retail and institutional investors alike.